Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
causes of death
myelodysplastic syndromes
relative survival
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
16
10
2022
received:
11
06
2022
accepted:
19
10
2022
pubmed:
7
11
2022
medline:
7
2
2023
entrez:
6
11
2022
Statut:
ppublish
Résumé
Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-461Subventions
Organisme : European Union's Horizon 2020 research and innovation program under grant agreement No 634789 - 'Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time'.
ID : 634789
Organisme : Amgen Limited
Organisme : Celgene International
Organisme : Janssen Pharmaceuticals
Organisme : Novartis Pharmacy B.V. Oncology Europe
Organisme : Takeda Pharmaceuticals International
Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Greenberg BP, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-88.
Greenberg PL, Tuechler H. Revised international prognostic scoring system for MDS. Blood. 2012;120:2454-65.
de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170:372-83.
Nachtkamp K, Stark R, Strupp C, Kündgen A, Giagounidis A, Aul C, et al. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016;95:937-44.
Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116:2174-9.
Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, et al. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017;1:2032-40.
Polednak AP. Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance. Cancer Epidemiol. 2013;37:569-74.
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377, 111-121.
Maynadié M, de Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98:230-8.
Roman E, Smith A, Appleton S, Crouch S, Kelly R, Kinsey S, et al. Myeloid malignancies in the real-world: occurrence, progression and survival in the UK's population-based Haematological malignancy research network 2004-15. Cancer Epidemiol. 2016;42:186-98.
Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96:441-9.
Jaffe ES, Harris NL, Stein H, Vardiman J. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, Oxford University Press; 2001.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-405.
Di Carlo V, Rachet B, Bannon F, Woods LM, Maringe C, Bonaventure A, et al. (2020) Life tables for the CONCORD programme.
Morel et al. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of the age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Hem. 1996;94:116-9.
Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. 116, 2174-2179. https://doi.org/10.1002/cncr.24984
Cordoba I, Gonzalez-Porras JR, Such E, Nomdedeu B, Luño E, de Paz R, et al. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. Leuk Res. 2012;36:287-92.
Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, et al. Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: a SEER-medicare analysis. Leukemia. 2020;34:1689-93.
Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847-52.
Merz A, Germing U, Kobbe G, Kaivers J, Jauch A, Radujkovic A, et al. EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J. 2019;9:85.
Jeong HY, Kang WS, Hong MH, Jeong HC, Shin MG, Jeong MH, et al. 5-azacytidine modulates interferon regulatory factor 1 in macrophages to exert a cardioprotective effect. Sci Rep. 2015;5:1-13.